Pharmaco-phospho-proteo-genomics of paediatric high-grade glioma (HGG)

Associate Professor Matt Dun from The University of Newcastle, Hunter Medical Research Institute is researching tumour genomics and protein architecture to establish patient-specific therapeutic options.
Associate Professor Matt Dun from The University of Newcastle, Hunter Medical Research Institute is researching tumour genomics and protein architecture to establish patient-specific therapeutic options.

Recipient: Associate Professor Matt Dun
Institute: The University of Newcastle, Hunter Medical Research Institute
Funding: $300,000 October 2021 to September 2024

This project focuses on improving treatment and survival for children with some of the most high-risk brain cancers.

Brain cancer accounts for 40 percent of paediatric cancer deaths. There has been no significant improvement in survival rates in decades. High-grade gliomas (HGG) are particularly aggressive and deadly brain tumours.

Genetic mutations alter the activity of proteins controlling the growth and survival of cancer cells. For children diagnosed with HGG, we are yet to understand how these pathways function.

This project, led by Associate Professor Matt Dun, will combine the investigation of tumour genomics and protein architecture to establish patient-specific therapeutic options with the greatest chance of survival.